Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V7PL
|
|||
| Former ID |
DIB007767
|
|||
| Drug Name |
Lefradafiban
|
|||
| Synonyms |
BIBU-104; BIBU-104XX; BIBV-104
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Angina pectoris [ICD-11: BA40; ICD-9: 413] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H25N3O6
|
|||
| Canonical SMILES |
COC(=O)CC1CC(NC1=O)COC2=CC=C(C=C2)C3=CC=C(C=C3)C(=NC(=O)OC)N
|
|||
| InChI |
1S/C23H25N3O6/c1-30-20(27)12-17-11-18(25-22(17)28)13-32-19-9-7-15(8-10-19)14-3-5-16(6-4-14)21(24)26-23(29)31-2/h3-10,17-18H,11-13H2,1-2H3,(H,25,28)(H2,24,26,29)/t17-,18-/m0/s1
|
|||
| InChIKey |
PGCFXITVMNNKON-ROUUACIJSA-N
|
|||
| CAS Number |
CAS 149503-79-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:60634
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02264106) Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects. U.S. National Institutes ofHealth. | |||
| REF 2 | Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.